DZ Bank
GBT

DZ Bank’s Global Blood Therapeutics, Inc. GBT Stock Holding History

DZ Bank’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-20,400
Closed -$985K – 1137
2018
Q1 		$985K Buy
+20,400
New +$1.14M ﹤0.01% 663

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DZ Bank's GBT Position: Q2 2018 in Review

DZ Bank sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2018, closing a stake of 20,400 shares — an estimated $985K sold.

DZ Bank first reported a position in GBT in Q1 2018 and held it in 1 quarter. The position peaked at $985K in Q1 2018. 196 funds tracked by Wall St. Rank hold GBT as of Q2 2018.

  • DZ Bank reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • DZ Bank sold 20,400 Global Blood Therapeutics, Inc. shares in Q2 2018, an estimated $985K.
  • DZ Bank first reported a position in Global Blood Therapeutics, Inc. in Q1 2018 and held it in 1 quarter.
  • DZ Bank's Global Blood Therapeutics, Inc. position peaked at $985K in Q1 2018.
  • 196 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2018.

Based on DZ Bank's 13F filing for Q2 2018, filed 14 Aug 2018.